Press Release RSS Feed (opens in new window)
Press release year list 2021 2020 2019 2018 2017
October 8, 2021
Guardant Health to Report Third Quarter Financial Results on November 4, 2021
October 5, 2021
Guardant Health Initiates ORACLE Study to Evaluate Performance of Guardant Reveal™ Blood Test to Predict Recurrence Across Early-Stage Cancers
September 15, 2021
Guardant Health Showcases Data at ESMO 2021 Demonstrating Utility of Guardant360® Liquid Biopsy to Obtain Comprehensive Molecular Information to Guide Targeted Therapy Options for Late-Stage Cancers
September 7, 2021
New Data at IASLC 2021 World Conference on Lung Cancer Demonstrates Advantages of Using the Guardant360® Liquid Biopsy Blood Test for Comprehensive Genomic Profiling in Advanced Lung Cancer
September 2, 2021
Guardant Health to Participate in the Morgan Stanley Global Healthcare Conference
August 6, 2021
Guardant Health to Participate in the UBS Genomics 2.0 and MedTech Innovations Summit
August 5, 2021
Guardant Health Announces New Leadership Structure Aligned with Strategic Growth Objectives and Expands Board of Directors
August 5, 2021
Guardant Health Reports Second Quarter 2021 Financial Results
July 20, 2021
Fight Colorectal Cancer and Guardant Health Join Forces to Recognize Excellence in Overcoming Challenges to Colorectal Cancer Screening During Pandemic
July 13, 2021
Guardant Health to Report Second Quarter Financial Results on August 5, 2021
June 22, 2021
Guardant Health Expands Guardant360® Portfolio With New Tests for Treatment Response Monitoring and Complete Genomic Profiling
June 18, 2021
CORRECTING and REPLACING Study Shows Guardant Reveal™ Blood-Only Liquid Biopsy Test Predicts Risk for Colorectal Cancer Recurrence with Industry-Leading Sensitivity
June 18, 2021
CORRECTING and REPLACING Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Utility of Liquid Biopsy in Early- and Late-Stage Cancers
June 8, 2021
Guardant Health Announces Appointment of Chris Freeman as Chief Commercial Officer
June 4, 2021
Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Blood Test Highly Accurate in Detecting Colorectal Cancer in Patients With Early-Stage Cancer
May 28, 2021
Guardant360® CDx Receives FDA Approval as First and Only Liquid Biopsy Companion Diagnostic for Amgen’s LUMAKRAS™ (sotorasib) KRASG12C Inhibitor for Use in Advanced Non-Small Cell Lung Cancer
May 28, 2021
Guardant Health Files Lawsuit Against Natera for Misleading Oncologists
May 21, 2021
Guardant360® CDx Receives FDA Approval as Companion Diagnostic for Janssen’s RYBREVANT™ (amivantamab-vmjw) for Use in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
May 20, 2021
Guardant Health to Participate in Upcoming June Investor Conferences
May 6, 2021
Guardant Health Reports First Quarter 2021 Financial Results
May 3, 2021
Guardant Health Appoints Craig Eagle, MD as Chief Medical Officer
April 29, 2021
Guardant Health to Participate in the BofA Securities 2021 Healthcare Conference
April 27, 2021
Guardant Health Announces Collaboration With Daiichi Sankyo to Develop Guardant360® CDx as a Companion Diagnostic for Enhertu® in Advanced Metastatic Non-Small Cell Lung Cancer
April 12, 2021
Guardant Health to Report First Quarter Financial Results on May 6, 2021
April 10, 2021
Data at AACR Demonstrate Growing Clinical Utility of Guardant Health Liquid Biopsies in the Treatment and Management of Advanced Cancers
April 1, 2021
Guardant Health Receives New York State CLEP Approval for Guardant Reveal Blood Test to Detect and Monitor Residual Disease in Patients with Early-Stage Cancer
March 30, 2021
Guardant Health Receives ADLT Status from CMS for FDA-Approved Guardant360® CDx Test
March 26, 2021
Study Shows Guardant360 Liquid Biopsy Predicts Response to Pembrolizumab-Based Immunotherapy in Patients with Metastatic Non-Small Cell Lung Cancer
March 24, 2021
Guardant Health Joins Forces With Patient Advocacy Groups to Raise Awareness of Importance of Complete Biomarker Testing for Patients With Advanced Colorectal Cancer
March 2, 2021
Guardant360® CDx Liquid Biopsy CE-Marked for Comprehensive Tumor Mutation Profiling Across All Solid Cancers
February 24, 2021
Guardant Health Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Revenue Outlook for Full Year 2021
February 17, 2021
Guardant Health to Participate in Upcoming Investor Conferences
February 16, 2021
Guardant Health Launches Guardant Reveal™ Liquid Biopsy Test for Residual Disease and Recurrence Monitoring in Patients with Early-Stage Colorectal Cancer
February 4, 2021
Guardant Health to Report Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021
January 27, 2021
Head-to-Head Study Shows Guardant360 Liquid Biopsy Outperforms Tissue Biopsy for Comprehensive Genomic Profiling in Advanced Non-Small Cell Lung Cancer with Similar Outcomes
January 18, 2021
Guardant Health and Vall d’Hebron Institute of Oncology Announce Partnership to Establish First Guardant-Based Liquid Biopsy Testing Service in Europe
January 14, 2021
Guardant Health to Present Data at ASCO Gastrointestinal Cancers Symposium Showing Value of Liquid Biopsy to Advance Precision Oncology in Early to Late-Stage Colorectal Cancer